Targeting lysosomes to eradicate imatinib-resistant chronic myelogenous leukemia cells.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches.Frontiers in oncology · 2022
   Review
2. Somatostatin receptor mediated targeting of acute myeloid leukemia by photodynamic metal complexes for light induced apoptosis.Scientific reports · 2020
   Article
3. Dual lysosomal-mitochondrial targeting by antihistamines to eradicate leukaemic cells.EBioMedicine · 2019
   Article
4. High Expression of TET1 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia From Two Cohorts.EBioMedicine · 2018
   Article
5. Gleevec shifts APP processing from a β-cleavage to a nonamyloidogenic cleavage.Proceedings of the National Academy of Sciences of the United States of America · 2017
   Article
6. Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux.Autophagy · 2015
   Article
7. All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.Oncotarget · 2012
   Article
8. Apoptosis and autophagy have opposite roles on imatinib-induced K562 leukemia cell senescence.Cell death & disease · 2012
   Article
9. BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients.Oncotarget · 2012
   Article
10. Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells.Oncotarget · 2011
    Article
11. Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20-243 CrossMab.mAbs
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as